Biocon QIP: Firm sets floor price of ₹340.2 per share for ₹4,500 crore fundraising

"The fundraising committee of the company, at its meeting held on June 16, 2025, authorised the opening of the issue (qualified institutions placement) and approved the floor price for the issue at ₹340.2 per equity share," Biocon Ltd said in a regulatory filing.

On April 23, 2025, the company's board had approved raising the amount through the issue of securities.

The company's board approved raising the capital by way of the issuance of any instrument or security, including shares, non-convertible debt instruments along with warrants or any other convertible securities by way of qualified institutions placement or rights issue, etc.

“The issue price will be determined by the company in consultation with the book running lead managers appointed in relation to the issue,” Biocon further said.

On Monday, shares of Biocon closed at ₹356.95 apiece on the National Stock Exchange, rising 0.44%. 

Biocon this month has received approval in India for its liraglutide drug substance. Its wholly owned subsidiary, Biocon Pharma Limited, has also received approval for its Liraglutide drug product (6 mg/ml solution for injection in a pre-filled pen and cartridge) from the Drugs Controller General of India, CDSCO (Central Drugs Standard Control Organisation).

The approval is for the generic version of Victoza®, indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus in adults, adolescents and children aged 10 years and above, as an adjunct to diet and exercise.

For Q4 FY25, Biocon Ltd had reported a net profit zoomed 154% to ₹344.5 crore, compared to ₹135.5 crore a year earlier. Its revenue increased 12.8% year-on-year (YoY) to ₹4,417 crore.

For the quarter, Biocon’s earnings before interest, taxes, depreciation, and amortisation (EBITDA) surged 17.7% YoY to ₹1,078.2 crore as against ₹915.9 crore in the same quarter last year. The margin also expanded to 24.4% from 23.4% a year ago.